Company Overview of Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology, allergy/immunology, and urology. It offers its products and se...
Founded in 1963
Key Executives for Taiho Pharmaceutical Co., Ltd.
President and Representative Director
Chief Executive Officer of Otsuka Holdings Co.
Executive Vice President and Board Member
Compensation as of Fiscal Year 2014.
Taiho Pharmaceutical Co., Ltd. Key Developments
Taiho Pharmaceutical Co., Ltd. Announces Executive Changes
Jun 11 14
Taiho Pharmaceutical Co., Ltd. announced that changes of directors were approved on June 11, 2014 at Taiho's annual general shareholders' meeting and the meeting of Board of Directors. Koichi Matsuda was appointed as Executive Vice President (Board Member), Taiho Pharmaceutical Co., Ltd., effective June 11, 2014. Koichi Matsuda’s previous position was Executive Vice President and Representative Director, Taiho Pharmaceutical Co., Ltd. Tsuyoshi Tsukamoto as appointed as Director (Board Member), Head of Production Division, CMC Center, Taiho Pharmaceutical Co., Ltd., effective June 11, 2014. Tsuyoshi Tsukamoto’s previous position was Operating Officer, Head of Production Division, CMC Center, Taiho Pharmaceutical Co., Ltd. Naofumi Moriwaki resigned as Director (Board Member), Taiho Pharmaceutical Co., Ltd., effective June 11, 2014.
Taiho Pharmaceutical Co., Ltd. Announces Results from Phase III Breast Cancer Study
Jun 4 14
Taiho Pharmaceutical Co., Ltd. announced results from SELECT BC study, a Phase III randomized controlled study of taxane and TS-1 on metastatic breast cancer. For advanced, recurrent breast cancer with distant metastasis, SELECT BC is the Phase III clinical study that demonstrated the ability of TS-1 monotherapy for the first time to prolong life when used as a first line chemotherapy. The primary endpoint of overall survival (OS) was 35.0 months in the TS-1 arm and 37.2 months in the taxane arm, demonstrating the non-inferiority of TS-1 in OS (hazard ratio = 1.05, 95% confidence interval: 0.86 - 1.27, non-inferiority test p=0.015). In the TS-1 arm, the main adverse events of grade 3 or higher were neutropenia (6.8%), fatigue (3.3%), diarrhea (2.6%), and anorexia (2.6%). Alopecia was 4.9% for all grades. The SELECT BC study was conducted by the Comprehensive Support Project for Oncology Research of Public Health Research Foundation (PHRF-CSPOR) as a physician-initiated study under contract with and funded by Taiho. The study was designed based on the following concept. As the goals of the treatment of metastatic breast cancer are prolonged survival time and improvement of patients' quality of life (QOL), if OS is not inferior, then the selection of a drug as a first line chemotherapy would be based on adverse drug reactions and QOL, not on response rate. The study was conducted between October 2006 and July 2010 at 258 medical facilities in Japan. A total of 618 patients were registered for the study.
Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
May 12 14
Taiho Pharmaceutical Co., Ltd. announced results from its global Phase III RECOURSE trial on its oral combination anticancer drug TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC). The RECOURSE trial met its primary endpoint of demonstrating improvement in overall survival (OS) in patients with refractory mCRC whose disease had progressed after approved standard therapies. In this trial, TAS-102 appeared to be generally well tolerated and the toxicities were consistent with what was previously reported.
Similar Private Companies By Industry
Recent Private Companies Transactions